J&J’s Nipocalimab Shows Sustained Reduction in Lupus Disease Activity
- /
- /
- /
June 3rd 2026 Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a…
Trusted, human-reviewed articles across rheumatological, autoimmune and neurological conditions, for patients and the care-partners.
Join our community and we will send trusted education and updates for your condition.